Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07
Transcript : Intra-Cellular Therapies, Inc. - Special Call
04-16
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
04-16
AQ
Transcript : Intra-Cellular Therapies, Inc., Q4 2023 Earnings Call, Feb 22, 2024
02-22
Transcript : Intra-Cellular Therapies, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 08:15 AM
01-09
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
12-05
AQ
Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023
11-02
Transcript : Intra-Cellular Therapies, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:55 PM
12/09/23
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
11/09/23
AQ
Transcript : Intra-Cellular Therapies, Inc., Q2 2023 Earnings Call, Aug 03, 2023
03/08/23
Transcript : Intra-Cellular Therapies, Inc., Q1 2023 Earnings Call, May 04, 2023
04/05/23
Transcript : Intra-Cellular Therapies, Inc. - Special Call
28/03/23
Transcript : Intra-Cellular Therapies, Inc., Q4 2022 Earnings Call, Mar 01, 2023
01/03/23
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
08/12/22
AQ
Transcript : Intra-Cellular Therapies, Inc., Q3 2022 Earnings Call, Nov 03, 2022
03/11/22
Transcript : Intra-Cellular Therapies, Inc., Q2 2022 Earnings Call, Aug 09, 2022
09/08/22
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
13/06/22
AQ
Transcript : Intra-Cellular Therapies, Inc., Q1 2022 Earnings Call, May 10, 2022
10/05/22
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA (lumateperone) for Specific Patient Populations
26/04/22
AQ
Intra Cellular Therapies : Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations - Form 8-K
25/04/22
PU
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
25/04/22
AQ
Transcript : Intra-Cellular Therapies, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 07:30 AM
10/01/22
Transcript : Intra-Cellular Therapies, Inc., Q3 2021 Earnings Call, Nov 09, 2021
09/11/21
Transcript : Intra-Cellular Therapies, Inc. - Special Call
20/10/21
Transcript : Intra-Cellular Therapies, Inc., Q2 2021 Earnings Call, Aug 09, 2021
09/08/21
Transcript : Intra-Cellular Therapies, Inc., Q1 2021 Earnings Call, May 10, 2021
10/05/21
Transcript : Intra-Cellular Therapies, Inc. - Special Call
04/05/21
Transcript : Intra-Cellular Therapies, Inc., Q4 2020 Earnings Call, Feb 25, 2021
25/02/21
Transcript : Intra-Cellular Therapies, Inc., Q3 2020 Earnings Call, Nov 09, 2020
09/11/20
Intra-Cellular Therapies, Inc. Announces Executive Changes
02/10/20
CI
Intra Cellular Therapies : Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
02/10/20
AQ
INTRA-CELLULAR THERAPIES, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
01/10/20
AQ
Intra-Cellular Therapies, Inc. Announces Executive Changes
01/10/20
CI
Intra Cellular Therapies : Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
01/10/20
AQ
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
01/10/20
GL
Transcript : Intra-Cellular Therapies, Inc. - Special Call
09/09/20
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
27/02/19
GL
Transcript : Intra-Cellular Therapies, Inc., Q3 2018 Earnings Call, Nov 07, 2018
07/11/18
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results
07/11/18
GL
Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs
20/08/18
GL
Intra-Cellular Therapies Appoints Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs
20/08/18
CI